☆ 4.5 Article

Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037

EXPERT OPINION ON THERAPEUTIC PATENTS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pharmacology & Pharmacy

Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model

Nadja Uhlig et al.

Summary: The novel HPI compounds showed superior antiviral efficacy compared to the current standard HSV treatment represented by VACV in terms of survival rates, clinical scores, and reductions in viral load in the lungs and brains. These new drug candidates are promising for the treatment of HSV infections and warrant further translation into clinical trials.

ANTIVIRAL RESEARCH (2021)

添加到收藏夹

Article Immunology

Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2

Luke Cannon et al.

Summary: Recurrence of aciclovir-resistant HSV infections is common in immunosuppressed patients, with recommended second-line therapeutic agents associated with significant side effects. In this case, compassionate acquisition of the novel helicase-primase inhibitor pritelivir provided both symptomatic and virological control after second-line therapy failed. This represents the first clinical use of pritelivir in the United Kingdom.

INTERNATIONAL JOURNAL OF STD & AIDS (2021)

添加到收藏夹

Article Cell Biology

A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections

Christian Gege et al.

Summary: The text discusses the high prevalence of chronic herpesvirus infections and introduces a new HSV helicase-primase inhibitor, IM-250, with potential in vitro anti-herpes activity. IM-250 shows advantages over standard-of-care therapies in reducing disease duration, preventing recurrence, and maintaining effectiveness post-treatment cessation.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Review Virology

Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster

Kimiyasu Shiraki et al.

Summary: Acyclovir, valacyclovir, and famciclovir are commonly used for the treatment of herpes simplex virus and varicella-zoster virus infections. However, recent studies have shown that amenamevir, a helicase-primase inhibitor, has novel mechanisms of action against these viruses with promising clinical efficacy. Its antiviral activity is not influenced by the viral replication cycle and has been demonstrated to be non-inferior to valacyclovir in treating herpes zoster.

VIRUSES-BASEL (2021)

添加到收藏夹

Review Immunology

Overwhelming Evidence for a Major Role for Herpes Simplex Virus Type 1 (HSV1) in Alzheimer's Disease (AD); Underwhelming Evidence against

Ruth F. Itzhaki

Summary: The research suggests that HSV1 may play a significant role in Alzheimer's disease in APOE-ε4 carriers, and further investigation into disease prevention through vaccination or prolonged antiviral treatment of HSV1 infection in APOE-ε4 carriers is warranted.

VACCINES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Different solid forms for optimizing route of administration of the herpes drug Pritelivir

Helga Ruebsamen-Schaeff et al.

MEDCHEMCOMM (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis

Debra C. Quenelle et al.

ANTIVIRAL RESEARCH (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Antiviral Therapies for Herpesviruses: Current Agents and New Directions

Claudette L. Poole et al.

CLINICAL THERAPEUTICS (2018)

添加到收藏夹

Article Dermatology

Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study

Makoto Kawashima et al.

JOURNAL OF DERMATOLOGY (2017)

添加到收藏夹

Article Chemistry, Medicinal

Lead Development of Thiazolylsulfonamides with Carbonic Anhydrase Inhibitory Action

Fabrizio Carta et al.

JOURNAL OF MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Medicine, General & Internal

Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences A Randomized Clinical Trial

Anna Wald et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Medicine, General & Internal

Helicase-Primase Inhibitor Pritelivir for HSV-2 Infection

Anna Wald et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Review Pharmacology & Pharmacy

The DNA helicase-primase complex as a target for herpes viral infection

Sandra K. Weller et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2013)

添加到收藏夹

Article Chemistry, Medicinal

Exploring Activity Cliffs in Medicinal Chemistry Miniperspective

Dagmar Stumpfe et al.

JOURNAL OF MEDICINAL CHEMISTRY (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of Secondary'' Pharmaceutical Patents

Amy Kapczynski et al.

PLOS ONE (2012)

添加到收藏夹

Review Biochemistry & Molecular Biology

Blood-brain barrier permeability considerations for CNS-targeted compound library design

Stephen A. Hitchcock

CURRENT OPINION IN CHEMICAL BIOLOGY (2008)

添加到收藏夹

Article Microbiology

Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293

UAK Betz et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)

添加到收藏夹

Article Biochemistry & Molecular Biology

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

G Kleymann et al.

NATURE MEDICINE (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.